Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 2, 2014, Pages 266-276

  Fleuren, Emmy D G ^a   Versleijen Jonkers, Yvonne M H ^a   Boerman, Otto C ^a   van der Graaf, Winette T A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone cancer; Ewing sarcoma; Imaging; Osteosarcoma; Receptor tyrosine kinase

Indexed keywords

AMUVATINIB; ANAPLASTIC LYMPHOMA KINASE; AVE 1642; CEDIRANIB; CIXUTUMUMAB; CRIZOTINIB; DALOTUZUMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIGITUMUMAB; GANITUMAB; GEFITINIB; GSK 1904529 A; IMATINIB; INSULIN RECEPTOR; LENVATINIB; LINIFANIB; LINSITINIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; EWING SARCOMA; HUMAN; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; REVIEW; SOLID TUMOR;

BONE CANCER; EWING SARCOMA; IMAGING; OSTEOSARCOMA; RECEPTOR TYROSINE KINASE;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; SARCOMA, EWING;

EID: 84895999135     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.02.005     Document Type: Review

References (176)

1. Wachtel M., Schafer B.W. Targets for cancer therapy in childhood sarcomas. Cancer Treat. Rev. 2010, 36:318-327.
2. Grohar P.J., Helman L.J. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol. Ther. 2013, 137:216-224.
3. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353:172-187.
4. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer 2001, 8:161-173.
5. Gaspar N., Di G.A., Geoerger B., et al. Bone sarcomas: from biology to targeted therapies. Sarcoma 2012, 2012:301975.
6. Rikhof B., de Jong S., Suurmeijer A.J., Meijer C., van der Graaf W.T. The insulin-like growth factor system and sarcomas. J. Pathol. 2009, 217:469-482.
7. Kim S.Y., Toretsky J.A., Scher D., Helman L.J. The role of IGF-1R in pediatric malignancies. Oncologist 2009, 14:83-91.
8. Scotlandi K., Manara M.C., Serra M., et al. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur. J. Cancer 2011, 47:1258-1266.
9. van de Luijtgaarden A.C., Versleijen-Jonkers Y.M., Roeffen M.H., Schreuder H.W., Flucke U.E., van der Graaf W.T. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients. Target. Oncol. 2013, 8:253-260.
10. O'Neill A., Shah N., Zitomersky N., et al. Insulin-like growth factor 1 receptor as a therapeutic target in Ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma 2013, (article ID: 450478, http://dx.doi.org/10.1155/2013/450478).
11. van de Luijtgaarden A.C., Roeffen M.H., Leus M.A., et al. IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization. Future Oncol. 2013, 9:1733-1740.
12. Wang Y.H., Han X.D., Qiu Y., et al. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J. Surg. Oncol. 2012, 105:235-243.
13. Kappel C.C., Velez-Yanguas M.C., Hirschfeld S., Helman L.J. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 1994, 54:2803-2807.
14. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
15. Riggi N., Cironi L., Provero P., et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005, 65:11459-11468.
16. Bagatell R., Herzog C.E., Trippett T.M., et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin. Cancer Res. 2011, 17:611-619.
17. Kolb E.A., Kamara D., Zhang W., et al. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr. Blood Cancer 2010, 55:67-75.
18. Kurmasheva R.T., Dudkin L., Billups C., Debelenko L.V., Morton C.L., Houghton P.J. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009, 69:7662-7671.
19. Kurzrock R., Patnaik A., Aisner J., et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin. Cancer Res. 2010, 16:2458-2465.
20. Olmos D., Tan D.S., Jones R.L., Judson I.R. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010, 16:183-194.
21. Olmos D., Postel-Vinay S., Molife L.R., et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010, 11:129-135.
22. Huang F., Greer A., Hurlburt W., et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009, 69:2149.
23. Juergens H., Daw N.C., Geoerger B., et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 2011, 29:4534-4540.
24. Pappo A.S., Patel S.R., Crowley J., et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J. Clin. Oncol. 2011, 29:4541-4547.
25. Malempati S., Weigel B., Ingle A.M., et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 2012, 30:256-262.
26. Fleuren E.D., Versleijen-Jonkers Y.M., van de Luijtgaarden A.C., et al. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin. Cancer Res. 2011, 17:7693-7703.
27. Tolcher A.W., Sarantopoulos J., Patnaik A., et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 2009, 27:5800-5807.
28. Tap W.D., Demetri G., Barnette P., et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J. Clin. Oncol. 2012, 30:1849-1856.
29. Atzori F., Tabernero J., Cervantes A., et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17:6304-6312.
30. Schoffski P., Adkins D., Blay J.Y., et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur. J. Cancer 2013, 49:3219-3228.
31. Soria J.C., Massard C., Lazar V., et al. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur. J. Cancer 2013, 49:1799-1807.
32. Weigel B., Malempati S., Reid J.M., et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr. Blood Cancer 2014, 61:452-456.
33. Basu B., Olmos D., de Bono J.S. Targeting IGF-1R: throwing out the baby with the bathwater?. Br. J. Cancer 2011, 104:1-3.
34. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr. Pharm. Des. 2007, 13:671-686.
35. Frasca F., Pandini C., Scalia P., et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 1999, 19:3278-3288.
36. Pandini G., Vigneri R., Costantino A., et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin. Cancer Res. 1999, 5:1935-1944.
37. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 2002, 277:39684-39695.
38. Avnet S., Sciacca L., Salerno M., et al. Insulin receptor isoform a and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009, 69:2443-2452.
39. Kuijjer M.L., Peterse E.F., van den Akker B.E., et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 2013, 13:245.
40. Sabbatini P., Rowand J.L., Groy A., et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin. Cancer Res. 2009, 15:3058-3067.
41. Olmos D., Martins A.S., Jones R.L., Alam S., Scurr M., Judson I. Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011, (article ID: 402508, http://dx.doi.org/10.1155/2011/402508).
42. Macaulay V.M., Middleton M.R., Eckhardt S.G., Juergens R.A., Stephens A.W., Poondru S., McCarthy S.P., Gadgeel S.M. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28(Suppl.; abstract 3016). (Ref Type: Abstract).
43. Pulford K., Morris S.W., Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell. Physiol. 2004, 199:330-358.
44. Iwahara T., Fujimoto J., Wen D., et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997, 14:439-449.
45. Dirks W.G., Fahnrich S., Lis Y., Becker E., MacLeod R.A., Drexler H.G. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int. J. Cancer 2002, 100:49-56.
46. Fleuren E.D., Roeffen M.H., Leenders W.P., et al. Expression and clinical relevance of MET and ALK in Ewing sarcomas. Int. J. Cancer 2013, 133:427-436.
47. Li X.Q., Hisaoka M., Shi D.R., Zhu X.Z., Hashimoto H. Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum. Pathol. 2004, 35:711-721.
48. Sabbatini P., Korenchuk S., Rowand J.L., et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 2009, 8:2811-2820.
49. Mosse Y.P., Lim M.S., Voss S.D., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013, 14:472-480.
50. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7:493-507.
51. Freeman S.S., Allen S.W., Ganti R., et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008, 113:1453-1461.
52. Hughes D.P.M. Novel agents in development for pediatric sarcomas. Curr. Opin. Oncol. 2009, 21:332-337.
53. Kersting C., Gebert C., Agelopoulos K., et al. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin. Cancer Res. 2007, 13:2998-3005.
54. Andersson M.K., Aman P. Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Cancer Cell Int. 2008, 8:1.
55. Chernoguz A., Crawford K., Donovan E., et al. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model. J. Surg. Res. 2012, 173(173):1-9.
56. Daw N.C., Furman W.L., Stewart C.F., et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group study. J. Clin. Oncol. 2005, 23:6172-6180.
57. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
58. van Cruijsen H., Voest E.E., Punt C.J.A., et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur. J. Cancer 2010, 46:901-911.
59. Shim A.H.R., Liu H.L., Focia P.J., Chen X.Y., Lin P.C., He X.L. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11307-11312.
60. Kubo T., Piperdi S., Rosenblum J., et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008, 112:2119-2129.
61. Merchant M.S., Woo C.W., Mackall C.L., Thiele C.J. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J. Natl. Cancer Inst. 2002, 94:1673-1679.
62. Sulzbacher I., Birner P., Trieb K., Traxler M., Lang S., Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod. Pathol. 2003, 16:66-71.
63. Sulzbacher I., Birner P., Dominkus M., Pichlhofer B., Mazal P.R. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome. Pathology 2010, 42:664-668.
64. Uren A., Merchant M.S., Sun C.J., et al. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003, 22:2334-2342.
65. Bozzi F., Negri T., Negri T., et al. Evidence for activation of KIT, PDGFR alpha, and PDGFR beta receptors in the Ewing sarcoma family of tumors. Cancer 2007, 109:1638-1645.
66. Mcgary E.C., Weber K., Mills L., et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin. Cancer Res. 2002, 8:3584-3591.
67. Do I., Araujo E.S., Kalil R.K., et al. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Pathol. Res. Pract. 2007, 203:127-134.
68. Wang Y.X., Mandal D., Wang S.Z., et al. Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo 2009, 23:903-909.
69. Gonzalez I., Andreu E.J., Panizo A., et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell Factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin. Cancer Res. 2004, 10:751-761.
70. Timeus F., Crescenzio N., Fandi A., Doria A., Foglia L., Di Montezemolo L.C. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol. Rep. 2008, 19:353-359.
71. Shor A.C., Keschman E.A., Lee F.Y., et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res. 2007, 67:2800-2808.
72. Kolb E.A., Gorlick R., Houghton P.J., et al. Initial testing of dasatinib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 2008, 50:1198-1206.
73. Davis L.E., Hofmann N.E., Li G., et al. A case study of personalized therapy for osteosarcoma. Pediatr. Blood Cancer 2013, 60:1313-1319.
74. Maris J.M., Courtright J., Houghton P.J., et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 51:42-48.
75. Bond M., Bernstein M.L., Pappo A., et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 2008, 50:254-258.
76. Chao J., Budd G.T., Chu P.G., et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFR alpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 2010, 30:547-552.
77. Chugh Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model (vol 27, pg 3148, 2009). J. Clin. Oncol. 2009, 27:4630.
78. Dubois S.G., Shusterman S., Ingle A.M., et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Clin. Cancer Res. 2011, 17:5113-5122.
79. Smithey B.E., Pappo A.S., Hill D.A. C-kit expression in pediatric solid tumors - a comparative immunohistochemical study. Am. J. Surg. Pathol. 2002, 26:486-492.
80. Landuzzi L., De Giovanni C., Nicoletti G., et al. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am. J. Pathol. 2000, 157:2123-2131.
81. Scotlandi K., Manara M.C., Strammiello R., et al. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J. Clin. Oncol. 2003, 21:1952-1960.
82. Miiji L.N.O., Petrilli A.S., Di Cesare S., et al. C-kit expression in human osteosarcoma and in vitro assays. Int. J. Clin. Exp. Pathol. 2011, 4:775-781.
83. Sulzbacher I., Birner P., Toma C., Wick N., Mazal P.R. Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker. J. Clin. Pathol. 2007, 60:804-807.
84. Wei H., Zhao M.Q., Dong W., Yang Y., Li J.S. Expression of c-kit protein and mutational status of the c-kit gene in osteosarcoma and their clinicopathological significance. J. Int. Med. Res. 2008, 36:1008-1014.
85. Brave S.R., Ratcliffe K., Wilson Z., et al. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol. Cancer Ther. 2011, 10:861-873.
86. Hotfilder M., Lanvers C., Jurgens H., Boos J., Vormoor J. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother. Pharmacol. 2002, 50:167-169.
87. Naka T., Iwamoto Y., Shinohara N., Ushijima M., Chuman H., Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod. Pathol. 1997, 10:832-838.
88. Ferracini R., Direnzo M.F., Scotlandi K., et al. The Met/Hgf receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995, 10:739-749.
89. Patane S., Avnet S., Coltella N., et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 2006, 66:4750-4757.
90. Scotlandi K., Baldini N., Oliviero M., et al. Expression of met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am. J. Pathol. 1996, 149:1209-1219.
91. Coltella N., Manara M.C., Cerisano V., et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 2003, 17:1162.
92. Sampson E.R., Martin B.A., Morris A.E., et al. The orally bioavailable Met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J. Bone Miner. Res. 2011, 26:1283-1294.
93. Migliore C., Giordano S. Molecular cancer therapy: can our expectation be MET?. Eur. J. Cancer 2008, 44:641-651.
94. Guan H., Zhou Z.C., Wang H., Jia S.F., Liu W.B., Kleinerman E.S. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin. Cancer Res. 2005, 11:2662-2669.
95. Kaya M., Wada T., Akatsuka T., et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin. Cancer Res. 2000, 6:572-577.
96. Kaya M., Wada T., Kawaguchi S., et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br. J. Cancer 2002, 86:864-869.
97. Kreuter M., Paulussen M., Boeckeler J., et al. Clinical significance of vascular endothelial growth factor - a expression in Ewing's sarcoma. Eur. J. Cancer 2006, 42:1904-1911.
98. Dubois S.G., Marina N., Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer 2010, 116:749-757.
99. Niswander L.M., Kim S.Y. Stratifying osteosarcoma: minimizing and maximizing therapy. Curr. Oncol. Rep. 2010, 12:266-270.
100. Maris J.M., Courtright J., Houghton P.J., et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50:581-587.
101. Glade Bender J.L., Adamson P.C., Reid J.M., et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group study. J. Clin. Oncol. 2008, 26:399-405.
102. Fox E., Aplenc R., Bagatell R., et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J. Clin. Oncol. 2010, 28:5174-5181.
103. van der Graaf W.T.A., Gelderblom H. New systemic therapy options for advanced sarcomas. Curr. Treat. Options in Oncol. 2012, 13:306-317.
104. Cao L., Yu Y.K., Darko I., et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008, 68:8039-8048.
105. Zha J.P., O'Brien C., Savage H., et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol. Cancer Ther. 2009, 8:2110-2121.
106. Guo L., Abraham J., Flynn D.C., Castranova V., Shi X., Qian Y. Individualized survival and treatment response predictions for breast cancers using phospho-EGFR, phospho-ER, phospho-HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and phospho-p70S6K proteins. Int. J. Biol. Markers 2007, 22:1-11.
107. Merseburger A.S., Hennenlotter J., Simon P., et al. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res. 2005, 25:1901-1907.
108. Aleksic T., Chitnis M.M., Perestenko O.V., et al. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res. 2010, 70:6412-6419.
109. Asmane I., Watkin E., Alberti L., et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur. J. Cancer 2012, 48:3027-3035.
110. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 2010:105-117.
111. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
112. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6:559-593.
113. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1:241-263.
114. Toledo S.R.C., Oliveira I.D., Okamoto O.K., et al. Bone deposition, bone resorption, and osteosarcoma. J. Orthop. Res. 2010, 28:1142-1148.
115. Naing A., Kurzrock R., Burger A.M., et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin. Cancer Res. 2011, 17:6052-6060.
116. Eary J.F., O'Sullivan F., O'Sullivan J., Conrad E.U. Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome. J. Nucl. Med. 2008, 49:1973-1979.
117. van de Luijtgaarden A.C., de Rooy J.W., de Geus-Oei L.F., van der Graaf W.T., Oyen W.J. Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. Cancer Imaging 2008, 8:s61-s68.
118. Denecke T., Hundsdorfer P., Misch D., et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:1842-1853.
119. Gaston L.L., di Bella C., Slavin J., Hicks R.J., Choong P.F. (18)F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. Skeletal Radiol. 2011, 40:1007-1015.
120. Gupta K., Pawaskar A., Basu S., et al. Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors. Clin. Nucl. Med. 2011, 36:973-977.
121. Hawkins D.S., Schuetze S.M., Butrynski J.E., et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J. Clin. Oncol. 2005, 23:8828-8834.
122. Kim D.H., Kim S.Y., Lee H.J., et al. Assessment of chemotherapy response using FDG-PET in pediatric bone tumors: a single institution experience. Cancer Res. Treat. 2011, 43:170-175.
123. Samuel A.M. PET/CT in pediatric oncology. Indian J. Cancer 2010, 47:360-370.
124. Bischoff M., Bischoff G., Buck A., et al. Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors. Arch. Orthop. Trauma Surg. 2010, 130:819-827.
125. Gerth H.U., Juergens K.U., Dirksen U., Gerss J., Schober O., Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J. Nucl. Med. 2007, 48:1932-1939.
126. Malempati S., Weigel B., Ingle A.M., et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 2012, 30:256-262.
127. Grignani G., Palmerini E., Dileo P., et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann. Oncol. 2012, 23:508-516.
128. Buck A.K., Herrmann K., zum Bueschenfelde C.M., et al. Imaging bone and soft tissue tumors with the proliferation marker [F-18]Fluorodeoxythymidine. Clin. Cancer Res. 2008, 14:2970-2977.
129. Fleuren E.D., Versleijen-Jonkers Y.M., Roeffen M.H., Franssen G.M., Houghton P., Oyen W., Boerman O., van der Graaf W.T. Temsirolimus is effective as a single agent and in combination with cisplatin or bevacizumab in preclinical osteosarcoma models. AACR Annual Meeting 2013 2013, (Ref Type: Abstract).
130. 2-R1507 fragments in Ewing sarcomas. Eur. J. Cancer 2013, 49:2851-2858.
131. Kolb E.A., Gorlick R., Lock R., et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2011, 56:595-603.
132. Tolmachev V., Malmberg J., Hofstrom C., et al. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule In-111-DOTA-Z(IGF1R:4551). J. Nucl. Med. 2012, 53:90-97.
133. Li S.L., Liang S.J., Guo N., Wu A.M., Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol. Immunother. 2000, 49:243-252.
134. Potratz J.C., Saunders D.N., Wai D.H., et al. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res. 2010, 70:8770-8781.
135. Huang F., Hurlburt W., Greer A., et al. Differential mechanisms of acquired resistance to insulin-like growth factor-I receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res. 2010, 70:7221-7231.
136. Garofalo C., Manara M.C., Nicoletti G., et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011, 30:2730-2740.
137. Fulzele K., DiGirolamo D.J., Liu Z., Xu J., Messina J.L., Clemens T.L. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem. 2007, 282:25649-25658.
138. Buck E., Gokhale P.C., Koujak S., et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 2010, 9:2652-2664.
139. Subbiah V., Naing A., Brown R.E., et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One 2011, 6:e18424.
140. Giaccone G., Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat. Rev. 2011, 37:456-464.
141. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
142. Krumbach R., Schuler J., Hofmann M., Giesemann T., Fiebig H.H., Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur. J. Cancer 2011, 47:1231-1243.
143. Duensing S., Duensing A. Targeted therapies of gastrointestinal stromal tumors (GIST)-the next frontiers. Biochem. Pharmacol. 2010, 80:575-583.
144. Mahadevan D., Cooke L., Riley C., et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007, 26:3909-3919.
145. Martins A.S., Mackintosh C., Martin D.H., et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin. Cancer Res. 2006, 12:3532-3540.
146. Dong J., Demarest S.J., Sereno A., et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol. Cancer Ther. 2010, 9:2593-2604.
147. Keir S.T., Maris J.M., Lock R., et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2010, 55:1126-1133.
148. Pignochino Y., Grignani G., Cavalloni G., et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol. Cancer 2009, 8.
149. Maruwge W., D'Arcy P., Folin A., et al. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco. Targets. Ther. 2008, 1:67-78.
150. Lamuraglia M., Payen T., Le Guillou-Buffelo D., Arditi M., Bridal L., Lucidarme O. Echo-contrast monitoring of sorafenib early efficacy: animal model for Ewing's sarcoma tumors. Cancer Res. 2012, 72(8, Supplement 1). (Ref Type: Abstract).
151. Takimoto C.H., Awada A. Safety and anti-tumor activity of sorafenib (Nexavar((R))) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother. Pharmacol. 2008, 61:535-548.
152. Raut C.P., Boucher Y., Duda D.G., et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 2012, 7:e26331.
153. Widemann B.C., Kim A., Fox E., et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group phase I consortium report. Clin. Cancer Res. 2012, 18:6011-6022.
154. Pignochino Y., Dell'aglio C., Basirico M., et al. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin. Cancer Res. 2013, 19:2117-2131.
155. Morgan S.S., Wang Z.J., Taverna P., Cranmer L.D. Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines. Eur. J. Cancer 2010, 7(Supplements 8). (abstract 193, Ref Type: Abstract).
156. Tibes R., Fine G., Choy G., et al. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013, 71:463-471.
157. Ikeda A.K., Judelson D.R., Federman N., et al. ABT-869 inhibits the proliferation of Ewing sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol. Cancer Ther. 2010, 9:653-660.
158. Asahina H., Tamura Y., Nokihara H., et al. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother. Pharmacol. 2012, 69:1477-1486.
159. Glen H., Mason S., Patel H., Macleod K., Brunton V.G. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumour cell migration and invasion. BMC Cancer 2011, 11:309.
160. Bruheim S., Kristian A., Uenaka T., et al. Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int. J. Cancer 2011, 129:742-750.
161. Yamada K., Yamamoto N., Yamada Y., et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17:2528-2537.
162. Mross K., Frost A., Steinbild S., et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res. 2012, 18:2658-2667.
163. van der Graaf W.T.A., Blay J.Y., Chawla S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
164. Kumar S., Mokhtari R.B., Sheikh R., et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 2011, 17:5656-5667.
165. Tanaka T., Yui Y., Naka N., et al. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy. Clin. Exp. Metastasis 2013, 30:369-379.
166. Keir S.T., Morton C.L., Wu J.R., Kurmasheva R.T., Houghton P.J., Smith M.A. Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2012, 59:586-588.
167. Glade Bender J.L., Lee A., Reid J.M., et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a Children's Oncology Group phase I consortium report. J. Clin. Oncol. 2013, 31:3034-3043.
168. Desar I.M., Timmer-Bonte J.N., Burger D.M., van der Graaf W.T., van Herpen C.M. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. Br. J. Cancer 2010, 103:1637-1643.
169. Semrad T.J., Eddings C., Dutia M.P., Christensen S., Lara P.N. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 2013, 24:636-640.
170. Benini S., Manara M.C., Baldini N., et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin. Cancer Res. 2001, 7:1790-1797.
171. Stewart C.F., Leggas M., Schuetz J.D., et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004, 64:7491-7499.
172. Furman W.L., Navid F., Daw N.C., et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J. Clin. Oncol. 2009, 27:4599-4604.
173. Pansy J., Fritsch P., Sovinz P., et al. Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors. Anticancer Drugs 2013, 24:198-203.
174. Venkatramani R., Malogolowkin M., Davidson T.B., May W., Sposto R., Mascarenhas L. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. PLoS One 2013, 8:e68416.
175. Wagner L., Turpin B., Nagarajan R., Weiss B., Cripe T., Geller J. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr. Blood Cancer 2013, 60:1447-1451.
176. Houghton P.J., Morton C.L., Tucker C., et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer 2007, 49:928-940.